Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20118 Phase 1 Study in Healthy Volunteers and Psoriasis Patients
NCT07033234Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- May 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HS-20118 in plaque psoriasis (4 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Incidence, severity and association with the study drug of adverse events, Number of participants with abnormalities of physical examination and 3 more. Started May 2025; status: recruiting.
02
Drugs
HS-20118
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07033234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07033234.